167 related articles for article (PubMed ID: 1585511)
1. M-VAC versus CisCA--chemotherapy in the treatment of advanced bladder cancer.
Heimbach D; Wirth M; Frohmüller H
Urol Int; 1992; 48(2):157-61. PubMed ID: 1585511
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
3. M-VAC chemotherapy in the management of locally advanced bladder cancer.
Skinner DG
J Urol; 1988 Mar; 139(3):570. PubMed ID: 3343745
[No Abstract] [Full Text] [Related]
4. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Sternberg CN; Yagoda A; Scher HI
Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
[No Abstract] [Full Text] [Related]
5. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.
Miller RJ; Bahnson RR; Banner B; Ernstoff MS; O'Donnell WF
Cancer; 1990 Jan; 65(2):207-10. PubMed ID: 2295043
[TBL] [Abstract][Full Text] [Related]
8. Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
Bishop JR; Moul JW; Maldonado L; McLeod DG
Urology; 1990 Oct; 36(4):373-7. PubMed ID: 2219624
[TBL] [Abstract][Full Text] [Related]
9. Analyses of factors affecting the outcome of combination chemotherapy in patients with advanced bladder cancer.
Igawa M; Ohkuchi T; Ueda M; Usui T; Kawanishi M
Eur Urol; 1991; 20(1):12-5. PubMed ID: 1743224
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of prophylactic adjuvant chemotherapy with CISCA in bladder tumors].
Bittard H
J Urol (Paris); 1988; 94(7):345-7. PubMed ID: 2464650
[TBL] [Abstract][Full Text] [Related]
12. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
13. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
14. Local response and long-term results of preoperative M-VAC regimen in regionally advanced transitional cell carcinoma of the bladder.
Abi-Aad AS; Stenzl A; Figlin R; deKernion JB
Eur J Cancer; 1993; 29A(8):1223-4. PubMed ID: 8518043
[No Abstract] [Full Text] [Related]
15. Incorporation of M-VAC combination chemotherapy in the treatment of patients with invasive and metastatic bladder cancer.
Soloway MS
Eur Urol; 1988; 14 Suppl 1():42. PubMed ID: 3181242
[No Abstract] [Full Text] [Related]
16. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.
Tannock I; Gospodarowicz M; Connolly J; Jewett M
J Urol; 1989 Aug; 142(2 Pt 1):289-92. PubMed ID: 2746745
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
[TBL] [Abstract][Full Text] [Related]
18. [Complete remission of brain metastasis of bladder cancer treated by M-VAC therapy].
Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K
Hinyokika Kiyo; 1989 Feb; 35(2):333-5. PubMed ID: 2735244
[TBL] [Abstract][Full Text] [Related]
19. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Bosl G; Watson RC; Hollander PS
Prog Clin Biol Res; 1988; 260():551-5. PubMed ID: 3283770
[No Abstract] [Full Text] [Related]
20. Possible alternative treatment for advanced transitional cell carcinoma of the urothelium (N+ and/or M+) in 1988.
Perrin P; Mouriquand P; Monsallier M; Devonec M
Prog Clin Biol Res; 1989; 303():617-9. PubMed ID: 2780666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
